An Observational Study, Called DEAR, to Learn More About Treatment With Darolutamide, Enzalutamide and Apalutamide in Men With Non-metastatic Castration-resistant Prostate Cancer in Real World Settings

NCT05362149 · clinicaltrials.gov ↗

COMPLETED

Status

870

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-metastatic Castration-resistant Prostate Cancer

Interventions

DRUG: Darolutamide (Nubeqa, BAY1841788)
DRUG: Enzalutamide
DRUG: Apalutamide

Sponsor

Bayer